IL-17A impairs host tolerance during airway chronic infection by Pseudomonas aeruginosa

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lorè, Nicola Ivan ^a   Cigana, Cristina ^a   Riva, Camilla ^a   De Fino, Ida ^a   Nonis, Alessandro ^b   Spagnuolo, Lorenza ^a   Sipione, Barbara ^a   Cariani, Lisa ^c   Girelli, Daniela ^c   Rossi, Giacomo ^d   Basso, Veronica ^a   Colombo, Carla ^c   Mondino, Anna ^a   Bragonzi, Alessandra ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IL17A PROTEIN, HUMAN; INTERLEUKIN 17;

ANIMAL; CYSTIC FIBROSIS; DISEASE MODEL; GENE KNOCKDOWN; GENETICS; HUMAN; IMMUNOLOGY; INCIDENCE; INNATE IMMUNITY; METABOLISM; MICROBIOLOGY; MOUSE; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; UPREGULATION;

ANIMALS; BIOMARKERS; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNITY, INNATE; INCIDENCE; INTERLEUKIN-17; MICE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; UP-REGULATION;

EID: 84970016009     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25937     Document Type: Article

References (47)

1. Medzhitov, R., Schneider, D. S. & Soares, M. P. Disease tolerance as a defense strategy. Science 335, 936-941, doi: 10. 1126/ science. 1214935 (2012).
2. Schneider, D. S. & Ayres, J. S. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Rev Immunol 8, 889-895, doi: 10. 1038/nri2432 (2008).
3. Raberg, L., Graham, A. L. & Read, A. F. Decomposing health: Tolerance and resistance to parasites in animals. Philos Trans R Soc Lond B Biol Sci 364, 37-49, doi: 10. 1098/rstb. 2008. 0184 (2009).
4. Cohen, T. S. & Prince, A. Cystic fibrosis: A mucosal immunodeficiency syndrome. Nat Med 18, 509-519, doi: 10. 1038/nm. 2715 (2012).
5. Hassett, D. J., Borchers, M. T. & Panos, R. J. Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives. J Microbiol 52, 211-226, doi: 10. 1007/s12275-014-4068-2 (2014).
6. Gallego, M. et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med 14, 103, doi: 10. 1186/1471-2466-14-103 (2014).
7. Isailovic, N., Daigo, K., Mantovani, A. & Selmi, C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun 60, 1-11, doi: S0896-8411(15)00059-1 (2015).
8. Jin, W. & Dong, C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect 2, e60, doi: 10. 1038/emi. 2013. 58 (2013).
9. McAleer, J. P. & Kolls, J. K. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev 260, 129-144, doi: 10. 1111/imr. 12183 (2014).
10. Reynolds, J. M., Angkasekwinai, P. & Dong, C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 21, 413-423, doi: 10. 1016/j. cytogfr. 2010. 10. 002 (2010).
11. Tan, H. L. & Rosenthal, M. IL-17 in lung disease: friend or foe? Thorax 68, 788-790, doi: 10. 1136/thoraxjnl-2013-203307 (2013).
12. Lore, N. I., Bragonzi, A. & Cigana, C. The IL-17A/IL-17RA axis in pulmonary defence and immunopathology. Cytokine and Growth Factor Reviews, doi: 10. 1016/j. cytogfr. 2016. 03. 009 (2016).
13. Ishigame, H. et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30, 108-119, doi: 10. 1016/j. immuni. 2008. 11. 009 (2009).
14. Dubin, P. J. et al. Interleukin-23-mediated inflammation in Pseudomonas aeruginosa pulmonary infection. Infection and immunity 80, 398-409, doi: 10. 1128/IAI. 05821-11 (2012).
15. Xu, X. et al. Role of Interleukin-17 in defense against pseudomonas aeruginosa infection in lungs. Int J Clin Exp Med 7, 809-816 (2014).
16. Liu, J. et al. The responses of gammadelta T-cells against acute Pseudomonas aeruginosa pulmonary infection in mice via interleukin-17. Pathog Dis 68, 44-51, doi: 10. 1111/2049-632X. 12043 (2013).
17. Muir, R. et al. Innate Lymphoid Cells are the Predominant Source of Interleukin-17A During the Early Pathogenesis of Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med, doi: 10. 1164/rccm. 201410-1782OC (2015).
18. Fogli, L. K. et al. T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia. J Immunol 191, 3100-3111, doi: 10. 4049/jimmunol. 1301360 (2013).
19. Dubin, P. J. & Kolls, J. K. IL-17 in cystic fibrosis: more than just Th17 cells. Am J Respir Crit Care Med 184, 155-157, doi: 10. 1164/ rccm. 201104-0617ED (2011).
20. Kolls, J. K. Helper T-cell type 17 cytokines and immunity in the lung. Ann Am Thorac Soc 11 Suppl 5, S284-286, doi: 10. 1513/ AnnalsATS. 201403-109AW (2014).
21. Tiringer, K. et al. A Th17-and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 187, 621-629, doi: 10. 1164/rccm. 201206-1150OC (2013).
22. Tan, H. L. et al. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 184, 252-258, doi: 10. 1164/rccm. 201102-0236OC (2011).
23. Brodlie, M., Corris, P. A., Lordan, J. & Ward, C. Interleukin-17 and cystic fibrosis lung disease. Am J Respir Crit Care Med 185, 108-109; author reply 109-110, doi: 185/1/108-a (2012).
24. Bragonzi, A. et al. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med 180, 138-145, doi: 10. 1164/rccm. 200812-1943OC (2009).
25. Cigana, C. et al. Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections. Sci Rep 6, 21465, doi: 10. 1038/srep21465 (2016).
26. Doring, G., Parameswaran, I. G. & Murphy, T. F. Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol Rev 35, 124-146, doi: 10. 1111/j. 1574-6976. 2010. 00237. x (2011).
27. Holtzman, M. J., Byers, D. E., Alexander-Brett, J. & Wang, X. The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nat Rev Immunol 14, 686-698, doi: 10. 1038/nri3739 (2014).
28. Dubin, P. J., McAllister, F. & Kolls, J. K. Is cystic fibrosis a TH17 disease? Inflamm Res 56, 221-227, doi: 10. 1007/s00011-007-6187-2 (2007).
29. Kukavica-Ibrulj, I., Facchini, M., Cigana, C., Levesque, R. C. & Bragonzi, A. Assessing Pseudomonas aeruginosa virulence and the host response using murine models of acute and chronic lung infection. Methods Mol Biol 1149, 757-771, doi: 10. 1007/978-1-4939-0473-0-58 (2014).
30. Bryant, D. M. & Mostov, K. E. From cells to organs: building polarized tissue. Nat Rev Mol Cell Biol 9, 887-901, doi: 10. 1038/ nrm2523 (2008).
31. Kudo, M. et al. IL-17A produced by alphabeta T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nat Med 18, 547-554, doi: 10. 1038/nm. 2684 (2012).
32. Wozniak, K. L., Hardison, S. E., Kolls, J. K. & Wormley, F. L. Role of IL-17A on resolution of pulmonary C. neoformans infection. PLos one 6, e17204, doi: 10. 1371/journal. pone. 0017204 (2011).
33. Gaffen, S. L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9, 556-567, doi: 10. 1038/nri2586 (2009).
34. Miossec, P. & Kolls, J. K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11, 763-776, doi: 10. 1038/ nrd3794 (2012).
35. Bartlett, H. S. & Million, R. P. Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov 14, 11-12, doi: 10. 1038/nrd4518 (2015).
36. Mi, S. et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and-independent mechanisms. J Immunol 187, 3003-3014, doi: 10. 4049/jimmunol. 1004081 (2011).
37. Mukherjee, S. et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol 179, 248-258, doi: 10. 1016/j. Ajpath. 2011. 03. 003 (2011).
38. Ivanov, S. & Linden, A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 30, 95-103, doi: 10. 1016/j. Tips. 2008. 11. 004 (2009).
39. Doring, G. et al. BIIL 284 reduces neutrophil numbers but increases P. Aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 13, 156-163, doi: 10. 1016/j. jcf. 2013. 10. 007 (2014).
40. Konstan, M. W. et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 13, 148-155, doi: 10. 1016/j. jcf. 2013. 12. 009 (2014).
41. Lore, N. I. et al. Cystic fibrosis-niche adaptation of Pseudomonas aeruginosa reduces virulence in multiple infection hosts. PLos one 7, e35648, doi: 10. 1371/journal. pone. 0035648 (2012).
42. Zaynagetdinov, R. et al. Identification of Myeloid Cell Subsets in Murine Lungs Using Flow Cytometry. Am J Resp Cell Mol 49, 180-189, doi: DOI 10. 1165/rcmb. 2012-0366MA (2013).
43. Price, A. E., Reinhardt, R. L., Liang, H. E. & Locksley, R. M. Marking and quantifying IL-17A-producing cells in vivo. PLos one 7, e39750, doi: 10. 1371/journal. pone. 0039750 (2012).
44. Bragonzi, A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol 300, 584-593, doi: 10. 1016/j. ijmm. 2010. 08. 012 (2010).
45. Cersini, A., Martino, M. C., Martini, I., Rossi, G. & Bernardini, M. L. Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutants. Infect Immun 71, 7002-7013 (2003).
46. Martino, M. C. et al. Mucosal lymphoid infiltrate dominates colonic pathological changes in murine experimental shigellosis. J Infect Dis 192, 136-148, doi: JID33751 (2005).
47. McLoughlin, D. et al. Pravastatin reduces Marfan aortic dilation. Circulation 124, S168-173, doi: 10. 1161/ CIRCULATIONAHA. 110. 012187 (2011).